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The purpose of this study was to investigate the utility of plasma pharmacokinetic and pharmacodynamic measures including plasma
deoxynucleosides, homocysteine and methylmalonic acid concentrations in understanding the time course and extent of the
inhibition of thymidylate synthase (TS) by pemetrexed in the context of a phase I/II combination study with vinorelbine. Eighteen
patients received supplementation with folic acid and Vitamin B12 1 week before beginning treatment with pemetrexed and
vinorelbine administered in a dose-escalating manner on a 21-day cycle. Heparinised blood samples were collected from consenting
patients in the first cycle for pharmacokinetic analyses and in the first two cycles for determination of plasma thymidine, deoxyuridine,
homocysteine and methylmalonic acid concentrations. These values were correlated with response and toxicity. Plasma deoxyuridine
was used as a measure of TS inhibition, and concentrations of deoxyuridine were significantly elevated relative to baseline on days 1
(Po0.01), 2 (Po0.001) and 3 (Po0.05) after treatment at all pemetrexed dose levels (400–700mgm
 2). The magnitude of
deoxyuridine elevation correlated with pemetrexed area under the plasma concentration–time curve (AUC) (r
2¼0.23, Po0.05).
However, deoxyuridine concentrations returned to baseline between 8 and 15 days after treatment with pemetrexed, suggesting
that inhibition of TS was not durable. Pemetrexed AUC correlated with the percentage decline (relative to baseline) in both platelets
(r
2¼0.58, Po0.001) and leucocytes (r
2¼0.26, Po0.05) at day 8. Baseline homocysteine was also significantly correlated with these
measures of haematological toxicity (r
2¼0.37, Po0.01 and r
2¼0.39, Po0.01, respectively). In addition, there was a significant
reduction of plasma homocysteine on days 8 (Po0.005) and 15 (Po0.05) in cycle 1 compared to baseline values. The results suggest
that the TS inhibitory effects of pemetrexed are short-lived and make the case for a more frequent schedule of administration such as
every 2 weeks. The lack of protracted TS inhibition may be due to concomitant vitamin administration, and this may be the
mechanism by which vitamins prevent life-threatening toxicity from pemetrexed. Baseline homocysteine concentration remains a
predictive marker for haematological toxicity even following folate supplementation.
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Pemetrexed, a multitargeted anti-folate, has shown activity in
various tumours, especially mesothelioma and non-small-cell lung
cancer (NSCLC) for which it is routinely used (Adjei, 2003).
Pemetrexed inhibits at least three of the enzymes involved in folate
metabolism, and pyrimidine and purine biosynthesis, as shown in
Figure 1. These include thymidylate synthase (TS), dihydrofolate
reductase (DHFR) and glycinamide ribonucleotide formyltrans-
ferase. However, inhibition of TS has been shown to be the primary
mechanism of action of pemetrexed (Grindey et al, 1992). TS, an
N
5,N
10-methylene tetrahydrofolate (methylene-THF)-dependent
enzyme, catalyses the reductive methylation of deoxyuridylate
(dUMP) to deoxythymidylate, the rate-limiting step in the de novo
synthesis of deoxythymidine triphosphate. Inhibition of DHFR by
pemetrexed reduces the regeneration of the essential coenzyme
methylene-THF thereby further enhancing the TS inhibitory
effects.
Inhibition of TS in tissues leads to intracellular accumulation of
dUMP and subsequent efflux of deoxyuridine (dUrd) into the
circulation. Accumulation of dUMP occurs as a direct consequence
of TS inhibition and also as a result of increased activity of other
enzymes, including ribonucleotide reductase (RR) and deoxycyti-
dylate (dCMP) deaminase (Maybaum et al, 1981). A number of
studies have indicated that plasma dUrd is an important
pharmacodynamic (PD) marker of TS inhibition (Mitchell et al,
1997; de Jonge et al, 2002; Ford et al, 2002; Rees et al, 2003)
especially with the use of the TS inhibitors AG337 (Nolatrexed)
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s(Jodrell et al, 1999; Estlin et al, 2001), ZD9331 (de Jonge et al, 2002;
Ford et al, 2002; Rees et al, 2003) and ZD1964 (raltitrexed) (Ford
et al, 2002; Horton et al, 2005); however, similar studies have not
been performed with pemetrexed.
Inhibition of TS may be offset by thymidine (TdR) salvage
pathways, and administration of exogenous TdR has been shown
to rescue tumour cell lines from pemetrexed-induced cytotoxicity
(Smith et al, 1999). Therefore, basal plasma TdR concentrations
might be predictive for response and toxicity with TS inhibitors.
However, correlative assessments of TdR and toxicity have not
previously been possible because of the lack of an appropriately
sensitive and specific assay. We have recently developed
and validated a liquid chromatography mass spectrometry
(LC-MS) assay that has demonstrated that human plasma TdR
concentrations are much lower than previously reported (Li et al,
2003).
Myelosuppression is the principal toxicity following treatment
with pemetrexed with 50% of patients experiencing grade 3/4
toxicity (Hanauske et al, 2001). Early in the preclinical evaluation
of pemetrexed, it became apparent that functional folate status was
an important factor in the activity and toxicity of this compound
(Worzalla et al, 1998). Methionine synthase, the enzyme which
catalyses the conversion of homocysteine (Hcy) to methionine
(Met), requires N
5-methyltetrafolate (methyl-THF) as a methyl
group donor and vitamin B12 for this reaction to proceed. When
methyl-THF and vitamin B12 levels are low, the conversion of Hcy
to Met decreases, resulting in increased concentrations of Hcy
(Figure 1). Thus, Hcy can be used as a marker for overall folate
status in the body. Likewise, vitamin B12 is a vital cofactor for
methylmalonyl coenzyme A mutase, and the level of methylma-
lonyl acid (MMA) increases as a result of vitamin B12 deficiency
(Savage et al, 1994; Lucock et al, 1999). It has been shown that
plasma Hcy and MMA levels are important markers in predicting
severe toxicity with pemetrexed (Niyikiza et al, 2002).
Administration of folic acid (0.5mg per mouth each day) and
vitamin B12 (1mg by intramuscular injection every 9 weeks)
commencing 1 week prior to treatment with pemetrexed has been
shown to reduce the incidence of life-threatening toxicity,
especially myelosuppression (Bunn et al, 2001). However, the use
of vitamin prophylaxis permits higher doses of pemetrexed to be
safely used, creating some uncertainty about the optimal schedule
and dose of this agent in the post-vitamin era. Consequently, a
comparison of the clinical pharmacokinetics (PK) of pemetrexed
with markers of its PD effects could clarify these issues of optimal
dose and schedule.
Previously, we have reported that the combination of peme-
trexed and vinorelbine is well tolerated and shows activity as first-
line treatment in advanced NSCLC patients (Clarke et al, 2005).
The objective of the current study was to further investigate the PD
of TS inhibitory effects by analysing plasma dUrd and TdR
concentrations and correlating them with toxicity in these patients.
By including a PK analysis of pemetrexed, another objective was
to assess possible PK–PD correlations during the first course
of treatment. Furthermore, we wished to correlate drug-induced
toxicities with functional folate status in vitamin-supplemented
patients.
MATERIALS AND METHODS
Eighteen patients from the phase I/II study of pemetrexed and
vinorelbine at the Sydney Cancer Centre at Royal Prince Alfred
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Figure 1 Folate involved in biosynthesis of pyrimidine, purine and methionine. AICARTfase, aminoimidazole carboxamide ribonucleotide transformylase;
AMP, adenosine monophosphate; GMP, guanosine monophosphate; FAICAR, formylaminoimidazole ribonucleotide; FGAR, formylglycinamide
ribonucleotide; FTHFL, formate-tetrahydrofolate ligase; MTHFR, methyltetrahydrofolate reductase; SAM, S-adenosylmethionine; SAH, S-adenosylhomo-
cysteine; SHMT, serine hydroxymethyltransferase.
Table 1 Patient demographics and clinical characteristics (n¼18)
Parameter No. of patients (%)
Male 13 (72%)
Median age, years (range) 58 (40–72)
Performance status
0 5 (28%)
1 13 (72%)
Disease status
Metastatic 17 (94%)
Locally advanced 1 (6%)
Prior adjuvant chemotherapy 0
Prior chemotherapy for metastatic disease 12 (67%)
Prior chemotherapy for locally advanced disease 1 (6%)
Prior radiotherapy 5 (27%)
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sHospital agreed to participate in this substudy. The demographics
and clinical characteristics of the patients are summarised in
Table 1. Eligibility criteria for patient recruitment were NSCLC
with at least aged 18 years with minimum estimated 12 weeks
life expectancy and performance status 0–2; good bone
marrow reserve (platelets4100 10
9l
 1, haemoglobin490gl
 1,
absolute granulocyte count42.0 10
9l
 1); adequate hepatic
function (bilirubino1.5 upper limit of normal (ULN), trans-
aminaseo3.0 ULN (unless liver metastases present)); and
adequate renal function (creatinine clearance40.75mls
 1,
albumin425gl
 1). Exclusion criteria were symptomatic brain
metastases, uncontrolled pleural or peritoneal effusions, and
inability to interrupt non-steroidal anti-inflammatory drugs. The
study was approved by the Human Ethics Research Committees of
the Central Sydney Area Health Service and the University of
Sydney.
Treatment
The patients received 400–700mgm
 2 pemetrexed (Alimta
r, Eli
Lilly and Company, Indianapolis, IN, USA) as a 10-min infusion
on day 1 of a 21-day cycle. Vinorelbine was infused at 15–
30mgm
 2 (approximately 6–10min infusion) on days 1 and 8 of a
21-day cycle. On day 1, the vinorelbine infusion began 30min after
the end of the pemetrexed infusion. This 21-day period defined
one cycle of therapy. All patients received supplementation with
folic acid (500mg p.o., daily) and vitamin B12 (1000mg i.m., every 9
weeks) commencing 1 week before the first cycle and continuing
until the discontinuation of chemotherapy.
Blood samples collection procedure
For the PK study, heparinised blood samples were collected at time
0 (baseline), 9.5min (end of pemetrexed infusion), 15, 30, 50min
(end of vinorelbine infusion), 1h, 1h 20min, 2, 4, 8, 24, 48 and
72h, for measurement of plasma pemetrexed and vinorelbine
concentrations over a 72-h period following the start of
pemetrexed administration in first cycle. In addition, blood
samples were also collected from patients on days 0, 1, 2, 3, 4, 8
and 15 of the first cycle and days 0, 8 and 15 of the second cycle for
measurement of TdR, dUrd, Hcy and MMA concentrations. Whole
blood was collected into prechilled heparinised blood tubes and
placed on ice immediately. Plasma was rapidly separated from
cellular components by centrifuging at 3300g at 41C for 15min.
Plasma was then stored at  801C and thawed just prior to analysis.
Pharmacokinetic analysis
Plasma pemetrexed concentrations were analysed at Taylor
Technology Inc. (Princeton, NJ, USA) using a validated liquid
chromatography electrospray ionisation with tandem mass spec-
trometric detection method over the concentration ranges of
10–2000 and 1000–200000ngml
 1 (Latz et al, 2006). Samples
were analysed for vinorelbine using a validated HPLC-fluorescence
detection method over the concentration range of 2–500ngml
 1
by Bioanalytical Laboratory Service (PPD Development,
Richmond, VA, USA).
Measurement of plasma TdR, dUrd, Hcy and MMA levels
Plasma TdR and dUrd levels were analysed using a validated
LC-MS method, which we previously published (Li et al, 2003,
2005). Briefly, plasma samples were extracted with strong anion-
exchange solid-phase extraction columns followed by HPLC
separation and atmospheric pressure chemical ionisation mass
spectrometry detection in a selected-ion monitoring mode. Plasma
Hcy and MMA were analysed by Douglas Hanley Moir Laboratory
(Sonic Clinical Trial Centre, North Ryde, NSW, Australia).
Statistical analysis
PK parameters were evaluated by compartmental and multiple
compartmental methods for pemetrexed and vinorelbine, respec-
tively (Lee and Amidon, 1996). The area under the plasma
concentration–time curve (AUC) was determined using the linear
trapezoidal method with extrapolation to infinity. Total plasma
clearance values of pemetrexed and vinorelbine for each patient
were calculated by dividing the dose administered by the AUC. The
values for plasma nucleosides, Hcy and methylmalonic acid at each
time point are expressed as mean±s.d. Statistical analysis of data
was achieved by Student’s t-tests (paired) and regression correla-
tion (GraphPad Prism). Po0.05 was considered to be statistically
significant.
RESULTS
Pharmacokinetic analysis
The full PK for the phase I/II trial have been published previously
(Clarke et al, 2005). The PK parameters for pemetrexed and
vinorelbine for the subgroup of patients included in this study are
summarised in Tables 2 and 3, respectively.
Plasma TdR, dUrd, Hcy and MMA analysis
Plasma dUrd and TdR concentrations during the first and second
cycles of treatment are shown in Figure 2. Plasma dUrd
concentrations were significantly elevated on days 1, 2 and 3 after
treatment at all pemetrexed dose levels. However, there was no
significant change of plasma TdR following pemetrexed treatment.
Mean pretreatment plasma dUrd and TdR concentrations of all 18
patients were 66.9±30.8 and 11.7±6.36nmoll
 1, respectively.
Plasma dUrd in treated patients was significantly increased
compared to baseline on days 1 (172nmoll
 1, 255%, Po0.01),
2 (210nmoll
 1, 315%, Po0.001) and 3 (170nmoll
 1, 252%,
Table 2 Summary of PK parameters for pemetrexed
Pemetrexed expressed as mean±s.d.
Dose (mgm
 2) 400 500 600 700
No. of patients 6534
AUC0–N (hmgml
 1) 130±36.4 194±75.8 187±30.5 216±29.3
Cmax (mgml
 1) 89.1±25.2 134±29.4 105±10.5 131±18.4
CLp (lh
 1m
 2) 3.29±0.96 2.59±0.94 3.28±0.58 3.32±0.48
t(1/2) (h) 2.57±1.13 2.58±1.47 1.91±0.49 3.00±0.85
Vss (lm
 2) 10.3±3.71 7.19±1.68 8.07±1.41 10.9±2.87
AUC¼area under the concentration–time curve; CLp¼plasma clearance;
Cmax¼maximum plasma concentration; PK¼pharmacokinetic; s.d.¼standard devia-
tion; t(1/2)¼terminal elimination half-life; Vss¼steady-state volume distribution.
Table 3 Summary of PK parameters for vinorelbine
Vinorelbine expressed as mean±s.d.
Dose (mgm
 2)1 52 33 0
No. of patients 7 3 8
AUC0–N (hmgml
 1) 0.88±0.60 1.78±0.38 2.04±1.03
Cmax (mgml
 1) 1.48±1.13 2.91±0.14 2.98±1.83
CLp (lh
 1m
 2) 27.4±22.9 12.9±0.62 18.7±9.73
t(1/2) (h) 48.3±15.2 36.5±8.21 42.0±11.6
Vss (lm
 2) 1067±543 1671±373 1649±1240
AUC¼area under the concentration–time curve; CLp¼plasma clearance;
Cmax¼maximum plasma concentration; PK¼pharmacokinetic; s.d.¼standard
deviation; t(1/2)¼terminal elimination half-life; Vss¼steady-state volume distribution.
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sPo0.05) when averaged for all doses. By day 4, the plasma dUrd
levels remained elevated relative to baseline, although this did not
reach statistical significance (103nmoll
 1, 154%, NS). Deoxy-
uridine concentrations returned to baseline by day 8. In contrast,
mean plasma TdR concentrations were 86, 94 and 96% of baseline
on days 1, 2 and 3, and this was not significantly different to
baseline values.
The basal Hcy and MMA concentrations were 9.3±2.95mmoll
 1
(range: 4.72–17.2) and 224±106nmoll
 1 (range: 97–412),
respectively for the 18 patients. Most of the patients (17 out of
18) had Hcy values within the normal range (5–13.9mmoll
 1), and
only one patient had elevated Hcy (17.2mmoll
 1). Five patients (5
out of 18) had abnormally high MMA levels and these ranged from
340 to 412nmoll
 1 (normal range: 73–271nmoll
 1). Baseline Hcy
was significantly correlated with baseline MMA (r
2¼0.40,
Po0.01), but only baseline Hcy correlated with the reduction (%
baseline) of both platelets (r
2¼0.37, Po0.01) and leucocytes
(r
2¼0.39, Po0.01) on day 8 of treatment cycle 1 (Figure 3). There
was a significant reduction in plasma Hcy on days 8 (Po0.005)
and 15 (Po0.05) compared to baseline values as shown in Figure 4.
There was also a trend towards reduction in MMA levels after
treatment; however, this did not achieve statistical significance.
There was no correlation between either baseline Hcy or MMA
concentrations with the maximum elevation of plasma dUrd in
treatment cycle 1.
The total body exposure of pemetrexed (AUC) was significantly
correlated with reduction (% baseline) of platelets (r
2¼0.58,
Po0.001) and leucocytes (r
2¼0.26, Po0.05) on day 8 and
maximum increase (% baseline) of dUrd (r
2¼0.23, Po0.05) on
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Figure 2 Plasma nucleoside concentrations and % of baseline changes following pemetrexed–vinorelbine treatment. Data are means±s.d.
þPo0.05,
þþPo0.01 and
þþþPo0.001 when compared with corresponding baseline values.
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Figure 3 Correlation between baseline Hcy and (A) baseline MMA (r
2¼0.40, Po0.01), (B) PLT (r
2¼0.37, Po0.01) and (C) WBC (r
2¼0.39, Po0.01)
on day 8 of treatment cycle 1.
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Figure 4 Plasma Hcy concentrations in treatment cycles 1 and 2. Data
are means±s.d.
þPo0.05 and
þþPo0.005 when compared with
baseline concentrations.
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sday 2 as shown in Figure 5. However, there was no significant
correlation between the change in plasma dUrd and platelet and
leucocyte counts on either day 8 or 15.
DISCUSSION
The objective of this study was to investigate PK–PD aspects of
pemetrexed in the setting of a phase I/II combination study. The
PK of pemetrexed and vinorelbine were consistent with data
obtained with single-agent chemotherapy (Marquet et al, 1992;
Leveque and Jehl, 1996; Sabot et al, 1998). There was no evidence
for PK interaction between the two drugs. In the current study,
measurement of plasma dUrd concentration showed that peme-
trexed administered at doses of 400–700mgm
 2 produced
consistent elevations in plasma dUrd, suggesting that plasma
exposure to pemetrexed was sufficient to induce TS inhibition in
patients. Indeed, the current results have demonstrated a clear
PK–PD relationship for TS inhibition in these patients (Figure 5).
On days 1–3, plasma dUrd levels were significantly higher than
baseline, and this may suggest rapid TS inhibition after dosing.
The maximum increase of dUrd level was observed on day 2
following which plasma dUrd gradually returned to baseline by
day 8, suggesting that TS inhibition was short-lived with this
schedule of pemetrexed. This pattern is comparable to previous
studies with the classical anti-folate raltitrexed (RTX), which
showed dUrd elevations on days 1–3 and which returned back to
baseline within 2 weeks of treatment (Ford et al, 2002; Horton et al,
2005).
Intracellularly, pemetrexed is polyglutamated by a reaction
catalysed by folylpolyglutamate synthase. Polyglutamated peme-
trexed is approximately 60-fold more potent in its inhibition of TS
than the parent monoglutamate compound (Shih et al, 1998) and is
retained intracellularly long term. Therefore, the highly inhibitory
polyglutamated forms would be expected to generate long-lived TS
inhibition. However, similar to the TS-selective inhibitor RTX, TS
inhibition by pemetrexed, as indicated by elevations in plasma
dUrd concentrations, was relatively transient. There are a number
of possible explanations for this. Firstly, plasma dUrd concentra-
tions may not be sensitive indicators of TS inhibition. However, in
a previous study of capecitabine we saw protracted elevation of
plasma dUrd concentrations that lasted for the entire course of
treatment (Li et al, 2007). An alternative explanation is that
inhibition of TS by folate-based agents is not durable, in spite of
intracellular polyglutamation, and can be competed out by
naturally occurring folates once plasma drug levels are reduced.
This competition would be enhanced by exogenous administration
of folic acid, which could explain why vitamin-supplemented
patients do not experience protracted, potentially lethal toxicity.
Regardless of the explanation, these data suggest that other
more frequent administration schedules of pemetrexed, such as
bi-weekly regimens, should be explored to optimise its antipro-
liferative effects. Although cell death produced by pemetrexed can
be prevented in culture through the addition of exogenous TdR,
the plasma concentration of TdR observed in patients is likely to
be too low to play a significant role in the modulation of
pemetrexed activity through salvage pathways. Therefore, human
plasma TdR level does not appear to be a useful PD phenotypic
marker for TS inhibition.
Because anti-folates can interfere with the normal metabolic
pathway of folates in the body, it might be reasonable to speculate
that treatment with pemetrexed would alter folate metabolism
and that this would be reflected by an elevation of plasma Hcy
concentration. Surprisingly, the current study has shown that
plasma Hcy was not elevated but instead decreased in the first
2 weeks following pemetrexed therapy (Figure 4). Indeed, it has
been previously reported that plasma Hcy concentrations are not
affected by pemetrexed (Niyikiza et al, 2002). However, patients
did not receive folate supplementation in that particular study.
Therefore, it is likely that the kinetics of reduction of plasma Hcy
observed in current study are the direct result of expansion of
intracellular folate pools by folate/B12 supplementation. This is
consistent with previous studies that have demonstrated that folate
supplementation, with or without additional B12 and B6, can
significantly lower plasma Hcy (Naurath et al, 1995; Refsum et al,
1996; Bronstrup et al, 1998; Homocysteine Lowering Trialists’
Collaboration, 1998; Bunn et al, 2001; Billion et al, 2002).
In the present study, a statistically significant relationship
between baseline Hcy and MMA was established in patients. This
correlation is consistent with similar observations in healthy
volunteers as well as a number of patient subset studies, although
MMA is usually indicative of cobalamin status whereas Hcy is the
preferred marker for folate deficiency (Valik et al, 2004). Indeed,
only baseline Hcy was statistically associated with increased risk of
neutropenia and thrombocytopenia on day 8 of treatment cycle 1
(Figure 3). This supports the notion that plasma Hcy is a more
specific marker for overall functional folate status and indicates
that baseline Hcy might be useful in predicting toxicity during
pemetrexed therapy or be used as support for increased
supplementation (either duration or dose) in individuals in whom
Hcy remains elevated after initial supplementation. In addition, it
also supports the current use of up-front supplementation with
folic acid and B12 in patients prior to treatment with pemetrexed.
In summary, the results of this study demonstrate PD changes
consistent with TS inhibition and a close PK–PD relationship
following pemetrexed–vinorelbine treatment. Baseline Hcy ap-
pears to be a better predictive marker than MMA for haemato-
logical toxicity. The current results also support the use of vitamin
supplementation to ensure normal vitamin B12 and folate status
to control haematologic toxicity secondary to pemetrexed
administration.
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Figure 5 Correlation between total body exposure of pemetrexed (AUC) and (A) dUrd on day 2 (r
2¼0.23, Po0.05), (B) PLT (r
2¼0.58, Po0.001)
and (C) WBC (r
2¼0.26, Po0.05) on day 8 of treatment cycle 1.
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